StockTipsArenaBeta

BUY Dr. Lal Path Labs Ltd. — Pradip Hotchandani, Prudent Corporate Advisory Services

BUYDr. Lal Path Labs Ltd.
Dr. Lal Path Labs share price target & all analyst calls

byPradip Hotchandani, Prudent Corporate Advisory ServicesHorizon: NA (inferred Swing (≤2wk))26 Aug 2026via CNBC Awaaz.

Entry₹1,940Inferred
Target₹2,100
Total upside +8.25% (call closed)
Stop loss₹1,890-2.58% risk
Exit₹1,89031 Aug 2026, 2:35 pm
Stop-loss hit-2.58%
Follow Pradip Hotchandani for new calls(20% target hit, 41 closed calls)Get alertsWatch LALPATHLAB for new buy/sell callsGet alertsSee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 31 Aug 2026
4 supporting0 opposing
Supports the BUY call (4)

Dr. Lal Ventures Private Limited, a wholly-owned subsidiary, has completed the subscription of a 30% stake in Neuome Technologies Private Limited. Neuome now becomes an associate of the company.

BSE · Company Update·27 Aug · 3d ago

(opens in new tab)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·25 Aug · 5d ago

3 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·19 Aug · 2w ago

Shri Bajrang Alliance Annual Report: Profit Up, Capacity Expansion Approved

NewsGoogle News·17 Aug · 2w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Lal Path Labs

All analyst calls on Dr. Lal Path Labs

More from Pradip Hotchandani, Prudent Corporate Advisory Services

Every call and its outcome